Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print.ABSTRACTNot available.PMID:38497158 | DOI:10.3324/haematol.2023.284109 (Source: Haematologica)
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Emilio Iannitto Simone Ferrero C ôme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord G Source Type: research
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print.ABSTRACTNot available.PMID:38497158 | DOI:10.3324/haematol.2023.284109 (Source: Haematologica)
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Emilio Iannitto Simone Ferrero C ôme Bommier Daniela Drandi Martina Ferrante Krimo Bouabdallah Sylvain Carras Guido Gini Vincent Camus Salvatrice Mancuso Luigi Marcheselli Angela Ferrari Michele Merli Benoit Tessoulin Caterina Stelitano Kheira Beldjord G Source Type: research
Bendamustine as lymphodepletion for brexucabtagene autoleucel therapy of mantle cell lymphoma
Mantle cell lymphoma (MCL) is a typically incurable, often aggressive mature B-cell neoplasm. Brexucabtagene autoleucel (brexu-cel) is approved for treatment of relapsed/refractory mantle cell lymphoma (MCL) based on the ZUMA-2 trial.1 The standard chemotherapy regimen used for lymphodepletion (LD) pre-brexu-cel is cyclophosphamide 500mg/m2 and fludarabine 30mg/m2 (cy/flu) on the fifth, fourth, and third days prior to brexu-cel. Due to a recent fludarabine shortage as well as institutional practice, we employed alternatives to fludarabine-based LD chemotherapy, in particular bendamustine. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 15, 2024 Category: Hematology Authors: Elise A. Chong, Emeline R. Chong, Dylan Therwhangher, Sunita D. Nasta, Daniel J. Landsburg, Stefan K. Barta, Jakub Svoboda, James N. Gerson, Guido Ghilardi, Luca Paruzzo, Joseph A. Fraietta, Elizabeth Weber, Natalie Stefano, David L. Porter, Noelle V. Fre Source Type: research
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study
Br J Haematol. 2024 Mar 14. doi: 10.1111/bjh.19407. Online ahead of print.ABSTRACTInfection and lymphopenia are established bendamustine-related complications. The relationship between lymphopenia severity and infection risk, and the role of antimicrobial prophylaxis, is not well described. This multicentre retrospective study analysed infection characteristics and antimicrobial prophylaxis in 302 bendamustine-treated indolent non-Hodgkin lymphoma patients. Lymphopenia (<1 × 109 /L) was near universal and time to lymphocyte recovery correlated with cumulative bendamustine dose. No association between lymphopenia severi...
Source: Herpes - March 14, 2024 Category: Infectious Diseases Authors: Kate Manos Leonid Churilov Andrew Grigg Pietro Di Ciaccio Jonathan Wong Usha Chandra Sekaran Joel Wight Zhong Goh Hayden Jina Llewyn Butler Costas K Yannakou Nada Hamad Gareth P Gregory Shane Gangatharan Tara Cochrane Eliza A Hawkes Masa Lasica Source Type: research
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study
Br J Haematol. 2024 Mar 14. doi: 10.1111/bjh.19407. Online ahead of print.ABSTRACTInfection and lymphopenia are established bendamustine-related complications. The relationship between lymphopenia severity and infection risk, and the role of antimicrobial prophylaxis, is not well described. This multicentre retrospective study analysed infection characteristics and antimicrobial prophylaxis in 302 bendamustine-treated indolent non-Hodgkin lymphoma patients. Lymphopenia (<1 × 109 /L) was near universal and time to lymphocyte recovery correlated with cumulative bendamustine dose. No association between lymphopenia severi...
Source: Herpes - March 14, 2024 Category: Infectious Diseases Authors: Kate Manos Leonid Churilov Andrew Grigg Pietro Di Ciaccio Jonathan Wong Usha Chandra Sekaran Joel Wight Zhong Goh Hayden Jina Llewyn Butler Costas K Yannakou Nada Hamad Gareth P Gregory Shane Gangatharan Tara Cochrane Eliza A Hawkes Masa Lasica Source Type: research
Successful treatment of lung cancer coexisting with B-cell lymphoma with pembrolizumab following rituximab-included chemotherapy: A case report
In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma.PMID:38476337 | PMC:PMC10928651 | DOI:10.3892/mco.2024.2731 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Daisuke Natori Hiroaki Ozasa Yusuke Shima Chisaki Mizumoto Keiichiro Suminaga Takashi Nomizo Hitomi Ajimizu Hironori Yoshida Toyohiro Hirai Source Type: research
Successful treatment of lung cancer coexisting with B-cell lymphoma with pembrolizumab following rituximab-included chemotherapy: A case report
In conclusion, the present study suggested that pembrolizumab, following rituximab-containing therapy, could be a treatment option for patients with lung cancer coexisting with MALT lymphoma.PMID:38476337 | PMC:PMC10928651 | DOI:10.3892/mco.2024.2731 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2024 Category: Cancer & Oncology Authors: Daisuke Natori Hiroaki Ozasa Yusuke Shima Chisaki Mizumoto Keiichiro Suminaga Takashi Nomizo Hitomi Ajimizu Hironori Yoshida Toyohiro Hirai Source Type: research
Anterior orbital ischemia secondary to type 1 cryoglobulinemia: A case report and literature review
CONCLUSION: Irial ischaemia should be considered as a potential in type 1 cryoglobulinaemia.PMID:38418361 | DOI:10.1016/j.revmed.2024.02.006 (Source: Revue de Medecine Interne)
Source: Revue de Medecine Interne - February 28, 2024 Category: Internal Medicine Authors: A Wyttynck M Raby F Le Gall A Dupuy M Soethoudt M Fouchard Source Type: research
Interstitial lung changes and persistent COVID ‐19 in a patient with follicular lymphoma: A case report
Herein, we report a case of COVID-19 persisting longer than 11 months which developed interstitial changes in the lungs that were recalcitrant to corticosteroid therapy. AbstractWe herein report a case of interstitial lung changes in a patient with prolonged coronavirus disease 2019 (COVID-19) with follicular lymphoma receiving rituximab and bendamustine who recovered after treatment with a combination therapy consisting of corticosteroids and immunosuppressive agents. There is currently no treatment strategy for prolonged pneumonitis following COVID-19, which can be life-threatening for immunocompromised patients. Thus...
Source: Respirology Case Reports - February 21, 2024 Category: Respiratory Medicine Authors: Makiko Yomota,
Masaru Tanaka,
Takayuki Kobayashi,
Masatake Kitano,
Saori Ikeda,
Yusuke Kanemasa,
Noriyo Yanagawa,
Yukio Hosomi Tags: CASE REPORT Source Type: research
Long-Term Remission After Chemotherapy with Bendamustine in a Patient with Refractory Large Granular Lymphocyte Leukemia
(Source: Indian Journal of Hematology and Blood Transfusion)
Source: Indian Journal of Hematology and Blood Transfusion - February 18, 2024 Category: Hematology Source Type: research
Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings
Adv Drug Deliv Rev. 2024 Feb 3;207:115193. doi: 10.1016/j.addr.2024.115193. Online ahead of print.ABSTRACTThe favorable benefit-risk profile of polatuzumab vedotin, as demonstrated in a pivotal Phase Ib/II randomized study (GO29365; NCT02257567), coupled with the need for effective therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), prompted the need to accelerate polatuzumab vedotin development. An integrated, fit-for-purpose clinical pharmacology package was designed to support regulatory approval. To address key clinical pharmacology questions without dedicated clinical pharmacology studies, we...
Source: Advanced Drug Delivery Reviews - February 4, 2024 Category: Drugs & Pharmacology Authors: Michael Z Liao Dan Lu Tong Lu Leonid Gibiansky Rong Deng Divya Samineni Randall Dere Andy Lin Jamie Hirata Ben-Quan Shen Donglu Zhang Dongwei Li Chunze Li Dale Miles Source Type: research
Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study
AbstractTo explore the optimal treatment for young patients with untreated mantle cell lymphoma (MCL), we compared the efficacy and safety of R-CHOP/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone/rituximab, dexamethasone, cytarabine and cisplatin) and R-BAP (rituximab, bendamustine, cytarabine, and prednisone) plus BTK (Bruton ’s tyrosine kinase) inhibitors in newly diagnosed patients. Eighty-three young patients (≤ 65 years old) with newly diagnosed MCL admitted to the First Affiliated Hospital of Zhengzhou University from January 1, 2014, to June 1, 2023, using R-CHOP/R-DHAP or R-BAP ...
Source: Annals of Hematology - February 3, 2024 Category: Hematology Source Type: research
